Cholyl-L-lysyl-fluorescein (CLF) is a fluorescent bile salt derivative that is being developed as an agent to determine in vivo liver function. However, the mechanisms of uptake and excretion by hepatocytes have not been rigorously studied. We have directly assessed the transport capacity of various hepatobiliary transporters for CLF. Uptake experiments were performed in CHO cells transfected with human NTCP, OATP1B1, OATP1B3 and OATP2B1.
JPET # 166991 4 4 Bile formation is a vital function of the liver and involves sodium-dependent and sodiumindependent uptake of bile salts from the portal blood as well as ATP-dependent canalicular excretion (Meier and Stieger, 2002) . Uptake into human hepatocytes involves Na + -dependent taurocholate cotransporting polypeptide, NTCP (SLC10A1) (Hagenbuch and Dawson, 2004; Dawson, et al., 2009) , and organic anion transporting polypeptides, OATP1B1
(SLCO1B1) and OATP1B3 (SLCO1B3) (Hagenbuch and Meier, 2004) . The bile salt export pump, BSEP (ABCB11) mediates biliary excretion of bile salts , the functional absence of which leads to severe liver disease. In addition, multidrug resistance associated protein 2, MRP2/Mrp2 (ABCC2/Abcc2) can transport bile salt metabolites (Akita, et al., 2001) . In various forms of intrahepatic cholestasis the biliary excretion capacity of ABCB11 and ABCC2 are decreased (Paumgartner, 2006) . As a consequence, hepatic bile salt levels rise intracellularly and subsequently, the uptake transporters NTCP, OATP1B1 and OATP1B3 are down regulated (Keitel, et al., 2005) . In primary biliary cirrhosis expression of bile salt uptake systems is reduced, while the canalicular export systems BSEP and MRP2 are minimally affected and the basolateral salvage system is induced (Zollner, et al., 2003; Zollner, et al., 2007) . Hence, determination of the clearance of substrates of hepatocellular transport systems could be used as a measure for in vivo liver function. In the past, sulfobromophtalein and indocyanine green were used to measure liver function as a test for measuring transport activities, but the former was abandoned because of the possibility of severe systemic reactions and the latter test is of concern in patients with iodine allergy (Sakka, 2007) .
Cholyl-L-lysyl-fluorescein (CLF) is a fluorescent bile salt and has been introduced as a potential agent to assess in vivo liver function (Milkiewicz, et al., 2000) . However, the transport systems involved in hepatic handling of CLF have not been investigated in molecular detail so far. Indications of the involvement of bile salt transporters in hepatic handling of CLF were found by several investigators: Mills et al. showed that the kinetics of CLF excretion into bile of rats is similar to that of glycocholate (Mills, et al., 1991) . In another study of Baxter et al. it (Baxter, et al., 1995) . Since ABCC2/Abcc2 is also capable of mediating the transport of (modified) bile salts this transporter should also be considered as a potential candidate for biliary CLF excretion.
However, Mills et al. concluded from a study with normal and TR -(Abcc2 deficient) Wistar rats that Abcc2 was hardly involved in the biliary excretion of CLF, based on the observation of similar biliary excretion in both strains (Mills, et al., 1999) . Carboxyfluorescein is an anion and a substrate for ABCC2/Abcc2 (Lee and Piquette-Miller, 2001) . In this respect the fluorescein moiety of CLF could render CLF to be an ABCC2/Abcc2 substrate. An indirect indication that CLF could be a substrate of ABCC2 was seen by Maglova et al. (Maglova, et al., 1995) . The excretion from couplets of cholylglycylamidofluorescein, which resembles CLF, could partially be inhibited by dinitrophenyl-glutathione, a model substrate for ABCC2 (Evers, et al., 1998) . CLF is going to be introduced as a novel agent for determination of in vivo liver function in a clinical setting. It is therefore crucial to define the mechanisms of uptake and excretion by the hepatocyte. Altered plasma clearance in patients with liver disease will reflect a change in expression and/or function of the transporters involved in uptake and biliary excretion of CLF. Since different transporters are regulated via different mechanisms, plasma clearance studies in patients can only be properly interpreted if it is known which transporters are involved. We come to the surprising finding that the established human bile salt transporters NTCP and ABCB11 (BSEP) are not at all capable of transporting CLF. Instead transport is mediated via OATP1B3 and ABCC2.
This article has not been copyedited and formatted. The final version may differ from this version. Boehringer-Mannheim (Almere, The Netherlands). Creatine-kinase was bought from RocheDiagnostics (Mannheim, Germany). All other chemicals and reagents were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Animals

Abcc2
-/-mice were bred at the National Cancer Institute (Amsterdam, The Netherlands). The production and characterization of Abcc2 -/-and Abcc3 -/-was decribed by Vlaming et al. (Vlaming, et al., 2006) and Zelcer et al. (Zelcer, et al., 2006) , respectively. All mice were bred against a FVB background.
Generation of CHO cells stably expressing NTCP and Cell Lines
cDNA for human NTCP (Hagenbuch and Meier, 1994) , 1997) was performed as described (Huber, et al., 2007) . CHO cells expressing OATP1B1, OATP1B3 and OATP2B1 were described previously (Gui, et al., 2008; Treiber, et al., 2007) .
Transport experiments with stably transfected cell lines
This article has not been copyedited and formatted. The final version may differ from this version. For all transport experiments, cells grown on 3 cm culture dishes were cultured for 24 h in media supplemented with 5 mmol/L sodium-butyrate to increase expression levels of transfected transporters (Palermo, et al., 1991) . Functionality of NTCP expressing CHO cells was assessed by transport studies with radioactively labelled taurocholate as described in (Huber et al., 2007) . Transport experiments with CLF were performed in the same buffers as for the radioactive substrates above. For visualization of CLF uptake, cells were immediately after the uptake experiment inspected with a Leica-DM-IRBE-inverted-microcope (LeicaMicrosystems, Wetzlar, Germany) equipped with a Hamamatsu-ORKA-ER-camera (Hamamatsu-Photonoics, Japan). To determine uptake of CLF, cells were solubilized by the addition of 2 ml 1% (w/v) Triton-X-100. After complete solubilization, 1.5 ml was used to measure fluorescence in a Perkin-Elmer LS-5 lumincescence-spectrometer set at λ exc 486 nm (slit 10 nm) and λ em 520 nm (slit 5 nm). Protein was determined with the bicinchoninic acid method using a kit from Interchim (Montfuçon, France). Transport data from OATP expressing cell lines were corrected for binding by subtracting 0 min time points (blank values) and except for figs. 2B and 2C were normalized per minute. Kinetic analysis was performed with nonlinear regression of the data to the Michaelis-Menten equation using
GraphPad PRISM-V-4.00 (GraphPad-Software-Inc., San Diego, CA)
Preparation of membrane vesicles
ABCC3 and ABCG2-recombinant baculovirus were a kind gift from Prof. P. Borst (Breedveld, et al., 2004; Zelcer, et al., 2001) . ABCB11-recombinant baculovirus was a kind gift from Dr.
R. Thompson (Byrne, et al., 2002) . The production of ABCB11-, ABCC2-, ABCC3-and ABCG2-recombinant baculovirus was as earlier described (Byrne, et al., 2002; de Waart, et al., 2006; de Waart, et al., 2009 ). Sf21 cells grown at 27°C were infected with ABCB11, ABCC2, ABCC3 and ABCG2-cDNA containing baculovirus. Cells were harvested at 2-4 days after infection. Membrane vesicle preparation was as described before (de Waart, et al., 2009 ). used: anti-his probe; sc-803 (Santa Cruz, USA), anti-ABCG2; BXP-21 (Maliepaard, et al., 2001 ), anti-ABCC2; M 2 III6 (Scheffer, et al., 2000) and anti-ABCC3; M 3 III21 (Scheffer, et al., 2000) . Immune complexes were visualized with horseradish-peroxidase-conjugated immunoglobulins and detected using chemiluminescence (Amersham, UK).
Western blotting and protein analysis
Transport assays with plasma membrane vesicles
Transport studies with membrane vesicles were performed using the rapid filtration technique as described (de Waart, et al., 2009) . Radiolabel was measured with a scintillation counter.
When CLF was used as a probe, filters were placed in a glass tube, 0.1% Triton-X-100 was added and the tubes vortexed. Samples were pipetted in 96-wells plates (Kartell, Noviglio, Italy) and the amount CLF quantitated by measurement of fluorescence at λ exc 485 nm and λ em 520 nm using a NovoStar (BMG-labtech, Offenburg, Germany).
Animal experiments
Male mice were housed in a pathogen-free animal facility on a 12 h light-dark cycle. All animal experiments were approved by the institutional animal care and use committee of the Academic Medical Center. Mice were anesthetized with a combination of Hypnorm (VetaPharma, UK; 11.8 mg/kg fluanisone and 0.37 mg/kg fentanyl-citrate) and Diazepam (Centrafarm, Etten-Leur, The Netherlands; 5.9 mg/kg valium). Body temperature was maintained at 36 ± 1°C on thermostatted heating pads. Fore clearance studies, mice were infused with CLF by injecting 100 µL (2 mmol/L) CLF in the tail vein. Subsequently, blood was drawn from the carotis at indicated time points. Blood samples were deproteinized by addition of two volumes methanol and the amount CLF in the supernatant was quantitated by measurement of fluorescence as described above.
For biliary secretion studies, gallbladders were cannulated with PE10 polyethylene tubing and 100 µL (1 mmol/L) CLF was injected in the tail vein. Bile was collected in 10 min fractions;
liver and blood were harvested at the end of the experiment. For intestinal uptake studies of TC and CLF, mice were anesthetized and the gallbladder cannulated as described above. Mice received both TC and CLF by injecting 100 µL (2 mmol/L) CLF into the ileum. Bile was collected every 15 min. Radioactivity was measured in a scintillation counter and CLF quantitated as described above.
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Results
First, the role of different hepatocellular bile salt transporters in the hepatic uptake of CLF was investigated. For this purpose CHO cells stably expressing NTCP were generated (CHO-NTCP) and characterized. Figure 1A shows no expression of NTCP in wild type CHO cells but clear plasma membrane expression of NTCP in stably transfected cells. Furthermore, uptake of taurocholate (TC) into these cells was strictly sodium dependent and was saturable with increasing taurocholate concentrations (Fig 1B) . The K m and the V max values were 16.0 µmol/L and 6738 pmol TC/mg protein/min, respectively, for sodium-dependent transport of TC (Fig 1B) . On the contrary, no sodium-dependent uptake of CLF mediated by NTCP could be observed by these cells as detected by fluorescence microscopy ( Fig. 2A ) and by quantitative fluorimetry of CLF (Fig. 2B) . Uptake of CLF into NTCP-expressing cells was negligible, sodium-independent and comparable to transport in wild type cells. (Fig 2B) .
Next, uptake of CLF mediated by OATP1B1, OATP1B3 and OATP2B1 was examined in wild type and stably transfected CHO cells. High, time dependent transport rates of CLF were only seen in OATP1B3 expressing CHO cells ( Fig. 2A and 2C , respectively). We consistently observed low, but significant uptake of CLF by OATP1B1 cells, but not by OATP2B1 cells (Fig 2A and 2C ), indicating that CLF is not a substrate for OATP2B1. OATP1B3 mediated CLF transport was concentration-dependent ( Fig 2D) with K m and the V max values of 4.6 ± 2.7 µmol/L and 213 ± 42 pmol CLF/mg protein/min, respectively (mean of three independent determinations). In the case of OATP1B1, uptake experiments with increasing CLF concentrations also showed evidence for saturability (not shown). However, due to a low signal to noise ratio, in particular at higher CLF concentrations, no determination of the kinetic parameters was possible. Furthermore, we investigated if transport of model compounds mediated by NTCP, OATP1B1, OATP1B3 and OATP2B1 could be inhibited by CLF despite CLF being a substrate for OATP1B3 only. Strikingly, CLF very efficiently inhibited the transport of TC via NTCP (Fig 3A) . Transport of TC via OATP1B3 could also be inhibited by CLF in a dose-dependent manner (Fig 3C) (Fig. 3) .
In order to test whether the canalicular ATP-dependent transporters ABCB11, ABCC2 and ABCG2, as well as the basolateral transporter ABCC3 mediate transport of CLF, we expressed these human proteins in Sf21 insect cells (Fig 4A) . Figure 4B shows that slight ATP-dependent uptake occurred in control vesicles, indicating that an endogenous transporter is able to take up CLF in an ATP-dependent fashion. ATP-dependent transport of CLF in ABCB11 and ABCG2 protein containing membrane vesicles was not higher than in control vesicles ( Fig 4C and D, respectively) . However, ABCC2 and ABCC3 containing membrane vesicles showed much higher CLF transport rates compared to control wild type Sf21 membrane vesicles (Fig 4E and F, respectively) . ABCC2 and ABCC3 mediated transport of CLF was concentration-dependent ( Fig 4G and H, (Fig. 5A ). Although we did not find any indication that CLF is a substrate for ABCB11, it contains the cholyl moiety and therefore, it might be able to inhibit bile salt transport via ABCB11. Indeed, TC transport could be inhibited by CLF in a dose dependent fashion and the concentration at which half maximal transport was observed was approximately 10 µmol/L (Fig 5B) . (Fig 7A) . As a consequence almost 70% of the CLF dose was excreted into bile in wild type mice within 20 min, whereas in the same time span less than 2% was excreted into bile in Abcc2 -/-mice. At 120 min after administration (Fig. 7B) , the cumulative biliary excretion of CLF was still significantly higher in wild type mice than in Abcc2 -/-mice (85% vs 32% of the administered dose) which resulted in a significantly higher hepatic retention of CLF in Abcc2 -/-vs wt mice (64% vs 1% of the administered dose) and in higher blood levels in Abcc2 -/-vs wt mice (1306 ± 749 nmol/L vs 83 ± 21 nmol/L). All these data indicate that in mice Abcc2 is the main transporter responsible for the biliary excretion of CLF. In line with the observations from Fig. 7A we observed that biliary output of CLF was not affected in Abcc3 -/-mice in comparison with wild type mice and we also found no differences in plasma and liver CLF contents ( Fig 7B) .
After excretion into bile and delivery into the duodenum, bile salts are taken up in the ileum via the apical sodium dependent bile acid transporter (ASBT) (Wong, et al., 1995 
Discussion
In this paper we show that uptake of CLF into hepatocytes is not likely to be mediated by NTCP, since we did not find any uptake of CLF into CHO cells expressing human NTCP.
This was not due to a non-functional protein, since these cells were fully capable of mediating the uptake of the natural occurring bile salt, TC. The ileal counterpart of hepatic NTCP is ASBT and it mediates transport of conjugated and unconjugated bile salts (Dawson, et al., 2009 ). We obtained indirect evidence to suggest that CLF is not transported via (murine)
Asbt: whereas TC injected in the ileal lumen of wild type mice was very efficiently recovered in bile, we found almost no CLF. These data suggest that both NTCP and Asbt, which are homologous sodium-dependent bile salt transporters, are unable to transport CLF. This result compares favourable with studies of bile salts conjugated via the side chain to fluorescein.
These bile salts are very poorly absorbed in the small intestine of rats (Holzinger, et al., 1997) . In contrast to CLF, another bile salt conjugate, taurocholyl-chlorambucil, was found to be a substrate for human NTCP (Kullak-Ublick, et al., 1997). The latter compound is a conjugate at the 3-OH group of the bile salt whereas CLF is conjugated at the side chain. In this context it is interesting that Baringhaus et al. determined the pharmacophore of both NTCP and ASBT and found that the 3-OH group is not essential for transport whereas the acidic side chain is (Baringhaus, et al., 1999) . Our new data are completely in line with this model.
The less specific bile salt transporters, OATP1B3 and, to a less extent, OATP1B1, turn out to be more likely candidates for uptake into the hepatocyte; which fits with the broad substrate specificity of these transporters (Hagenbuch and Meier, 2004 ).
Our data demonstrate, quite surprisingly but conclusively, that ABCC2/Abcc2 is the most prominent transporter responsible for biliary excretion of CLF and not ABCB11. In mice, the large majority of CLF in plasma is excreted into bile via Abcc2. It may be argued that the substrate specificity of human ABCC2 can be different from that in mice. However, in plasma membrane vesicle assays we demonstrated that transport of CLF via human ABCB11 is insignificant compared to that via human ABCC2. Therefore, in vitro studies with CLF This article has not been copyedited and formatted. The final version may differ from this version. (Gerloff, et al., 1998) . This is supported by the observation that in patients with a defect in bile acid conjugation, practically no unconjugatd bile acids are found in bile (Carlton, et al., 2003) . Early reports involving CLF suggested that ABCB11 was mainly involved in this process. Firstly, Mills et al. showed that in rats the biliary excretion rate of CLF after jugular vein injection has similar kinetics as the excretion of glycocholate, and different from that of fluorescein which was slower.
Therefore, the conclusion was drawn that CLF is also a substrate for ABCB11 like glycocholate. However, this experimental approach did not rule out the possibility that CLF is a substrate for ABCC2 but that the transport characteristics resemble those of glycocholate via ABCB11. Other indirect evidence that CLF is transported via ABCB11 was provided by
Baxter et al. who administered glycocholate and CLF to isolated perfused rat livers under recycling conditions, and observed that CLF was capable of increasing the phospholipid and cholesterol output in a similar way as glycocholate. Again, this does not rule out the possibility that CLF is excreted via Abcc2 and, once in the canalicular lumen, is subsequently able on the basis of its detergent properties to accept phospholipids and cholesterol from the membrane. It was shown in the same study that rat liver has a much greater capacity to transfer glycocholate from perfusate to bile than CLF and concomitantly, the increase in phospholipid and cholesterol output was less with CLF in comparison with glycocholate (Baxter, et al., 1995) . All in all, no direct evidence has ever been provided to support the contention that CLF is (mainly) taken up by the hepatocyte via NTCP/Ntcp and/or excreted into bile via ABCB11/Abcb11. Our present data show decisively that CLF is not transported via these bile salt transporters. Opposite to this finding is that cholylglycylamidofluorescein with CGamF, which contains one, therefore, CLF might be changed into a good ABCC2
substrate. Another way to identify the relevant transporters is the use of knockout animals.
Mills et al. used Abcc2 deficient, TR -rats and measured CLF in bile after injection of CLF in the jugular vein. The cumulative amount of CLF in bile was similar in TR -and normal Wistar rats after 30 min. They concluded from these data that Abcc2 is not the main transporter for CLF. However, we now directly show that Abcc2 is the main canalicular transporter for CLF in mice. We performed a similar but more extensive study using wild type and Abcc2 -/-mice.
In mice deficient in Abcc2, biliary excretion of CLF was strongly impaired and retained in the liver, which suggests that Abcc2 and not Abcb11 is the major transporter responsible for biliary excretion of CLF. As there is still residual biliary transport of CLF in Abcc2 -/-mice a contribution of Abcb11 and/or Abcg2, albeit small, cannot be excluded. Furthermore, reinterpretation of the data of the Mills et al. paper (1999) As CLF is being developed as an agent to assess liver function in patients it is crucial to know the exact mechanism of uptake into the hepatocyte and excretion into bile. Therefore, we ABCB11 as well as ABCC2 protein levels and localization were found to be maintained in PBC stages I and II (Zollner, et al., 2003; Zollner, et al., 2007) , reduced protein levels and a disruption of canalicular localization have been reported for ABCC2 in advanced PBC (stages III and IV) (Kojima, et al., 2003; Kullak-Ublick, et al., 2002) . In a pilot study CLF elimination was analysed in liver cirrhosis patients and seemed to be impaired in comparison to healthy volunteers (Milkiewicz, et al., 2000) . These cirrhotic patients suffered from high serum bilirubin and bile salt level, indicative of a cholestatic situation. In such conditions ABCC2 function may not only be impaired but ABCC3 expression may also be up regulated (Zollner, et al., 2003) . To investigate if patients have a cirrhotic liver a biopsy can proof this. However, a less invasive test would be more favourable. CLF could be used as an agent to assess in vivo liver function because in our study not only ABCC2 but also ABCC3 mediate the transport of CLF, cirrhotic patients may have a lowered biliary excretion rate of CLF, but also a higher basolateral excretion due to a higher expression of ABCC3. Importantly, analysis of plasma CLF clearance will not be compromised by enterohepatic circulation, because ileal uptake was low in our animal study. In conclusion, our data are of importance for the interpretation of plasma CLF clearance in patients with liver disease.
This article has not been copyedited and formatted. The final version may differ from this version. JPET # 166991 27 27 tested using two-sided Student's t-test: *P<0.05 for transport in the presence vs. absence of inhibitor.
Figure 6
Plasma clearance of CLF in mice.
Wild type, Abcc3 -/-and Abcc2 -/-mice received 100 µL of 2 mmol/L CLF by i.v. injection.
After the indicated time points blood was drawn. Data are expressed as the mean percentage of the initial CLF level at 2 min Significance was tested using two-sided Student's t-test: *P<0.05 for Abcc2 -/-vs wild type mice.
Figure 7
Biliary excretion of CLF in mice. 
Figure 8
Intestinal uptake of TC and CLF.
Appearance of TC and CLF in bile after ileal administration of 100 µL mixture of 2 mmol/L TC and CLF in wild type mice. Bile was collected after indicated time points. Data represent means ± SD. Cumulative biliary levels are expressed as percentage of applied dose.
Significance was tested using two-sided Student's t-test: *P<0.05 for TC uptake vs CLF uptake.
Figure 9
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